文献速递免疫规划

四价灭活流感疫苗与含交替B株的两种三价灭活流感疫苗在成人中的免疫原性和安全性比较:一项3期随机非劣效性研究

Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
PubMed 文献 · Vaccine · 2017-03-13

这项3期双盲研究将3484名≥18岁成人按2:1:1随机分配接种IIV4、IIV3-YAM或IIV3-VIC,主要目的是证明IIV4对两种IIV3的免疫应答非劣效。结果显示IIV4对匹配株的免疫应答非劣效,对IIV3中未包含的B株应答更优,各组安全性和耐受性相似。

要点

  • IIV4对匹配株的免疫应答非劣效于两种IIV3,对未匹配B株应答更优。
  • 不良事件总体轻微,52.9%的参与者报告不良事件。
  • 严重不良事件报告率IIV4为2.3%,IIV3-YAM为1.6%,IIV3-VIC为1.5%。

核心结论

  • IIV4对匹配株的免疫应答非劣效于美国许可的IIV3,对IIV3比较组未包含的未匹配B株应答更优。
  • 各疫苗组的安全性和耐受性特征相似。

研究设计与样本

  • 3期、双盲、随机、非劣效性研究,共纳入3484名≥18岁成人,按2:1:1随机分配接种IIV4(n=1741)、IIV3-YAM(n=871)或IIV3-VIC(n=872),并按年龄分层。
  • 主要目的是证明IIV4对IIV3-YAM和IIV3-VIC的免疫应答非劣效,非劣效界值为血凝抑制几何平均滴度(GMT)比值(IIV3/IIV4)双侧95%CI上限≤1.5,以及血清转化率(SCR)差值(IIV3-IIV4)双侧95%CI上限≤10%。
  • 接种后7天评估征集性局部和全身不良事件,接种后28天记录不良事件,接种后6个月记录严重不良事件。

主要发现

  • 调整后GMT比值(95%CI)对于A/H1N1为0.93(0.88,0.99),A/H3N2为0.93(0.88,0.98),B/YAM为0.87(IIV3-YAM;0.82,0.93),B/VIC为0.95(IIV3-VIC;0.88,1.03)。
  • SCR差值(95%CI)对于A/H1N1为-1.1(-4.5,2.3),A/H3N2为-1.7(-5.0,1.7),B/YAM为-3.2(IIV3-YAM;-7.4,0.9),B/VIC为-1.6(IIV3-VIC;-5.8,2.5)。
  • 不良事件总体轻微,52.9%的参与者报告不良事件。
  • 严重不良事件报告率IIV4为2.3%,IIV3-YAM为1.6%,IIV3-VIC为1.5%。

关键数值与推荐

  • 非劣效性判定标准:GMT比值(IIV3/IIV4)双侧95%CI上限≤1.5且SCR差值(IIV3-IIV4)双侧95%CI上限≤10%。
  • IIV4对匹配株的免疫应答非劣效于两种IIV3,对未匹配B株的应答优于IIV3比较组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination is the most effective means of influenza prevention. Efficacy of trivalent vaccines may be enhanced by including both B strain lineages. This phase 3, double-blind study assessed the immunogenicity and safety/tolerability of a quadrivalent inactivated influenza vaccine (IIV4) versus the United States (US)-licensed 2014-2015 trivalent inactivated influenza vaccine (IIV3-Yamagata [IIV3-YAM]; Afluria) and IIV3 containing the alternate Victoria B strain (IIV3-VIC) in adults ≥18years. METHODS: Participants (n=3484) were randomized 2:1:1 and stratified by age to receive IIV4 (n=1741), IIV3-YAM (n=871), or IIV3-VIC (n=872). The primary objective was to demonstrate noninferiority of the immunological response to IIV4 versus IIV3-YAM and IIV3-VIC. Noninferiority was assessed by hemagglutination inhibition geometric mean titer (GMT) ratio (IIV3/IIV4; upper bound of two-sided 95% confidence interval [CI]≤1.5) and seroconversion rate (SCR) difference (IIV3 - IIV4; upper bound of two-sided 95% CI≤10%) for vaccine strains. Solicited local and systemic adverse events (AEs) were assessed for 7days postvaccination, AEs recorded for 28days postvaccination, and serious AEs for 6months postvaccination. RESULTS: IIV4 elicited a noninferior immune response for matched strains, and superior response for unmatched B strains not contained in IIV3 comparators. Adjusted GMT ratios (95% CI) for A/H1N1, A/H3N2, B/YAM, and B/VIC strains were 0.93 (0.88, 0.99), 0.93 (0.88, 0.98), 0.87 (IIV3-YAM; 0.82, 0.93), and 0.95 (IIV3-VIC; 0.88, 1.03), respectively. Corresponding values for SCR differences (95% CI) were -1.1 (-4.5, 2.3), -1.7 (-5.0, 1.7), -3.2 (IIV3-YAM; -7.4, 0.9), and -1.6 (IIV3-VIC; -5.8, 2.5). AEs were generally mild and experienced by 52.9% of participants. Serious AEs were reported with a slightly higher frequency with IIV4 (2.3%) versus IIV3-YAM (1.6%) and IIV3-VIC (1.5%). CONCLUSIONS: IIV4 demonstrated immunological noninferiority to the US-licensed IIV3, and superiority for unmatched B strains not contained in IIV3 comparators. Safety/tolerability profiles were similar across vaccine groups. FUNDING: Seqirus; Clinicaltrials.gov: NCT02214225.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Treanor JT, Albano FR, Sawlwin DC, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study. Vaccine. 2017. PMID: 28302411. doi:10.1016/j.vaccine.2017.02.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。